Biosimilars

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

FDA approves Glenmark's generic inhaler with 180-day exclusivity, promising lower costs for millions and disrupting a major respiratory drug market.

The biopharma firm beats 2025 guidance on strong specialty and generic sales, forecasting another year of growth fueled by new product launches.

Eton Pharmaceuticals wins landmark FDA approval for DESMODA, a breakthrough liquid drug set to transform care for a rare condition by enabling precise, safe dosing.

Dupixent's landmark FDA approval offers a new, surgery-sparing option for a debilitating sinus disease, but questions of access and cost remain.

The FDA is reviewing a new, more affordable alternative to the costly arthritis drug Orencia, potentially saving patients and the healthcare system billions.

MAIA Pharmaceuticals will bring Teribone™, a proven therapy used in Japan, to the US, aiming to solve the critical patient adherence crisis in osteoporosis care.

With major grants from top foundations, Lario Therapeutics expands its precision neuroscience platform, offering new hope for complex neurological disorders.

New data on Spyre Therapeutics' SPY003 suggests a twice-yearly shot for IBD is possible, part of a broader strategy to challenge market giants.

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?

NervGen Pharma to unveil data showing its drug NVG-291 provides lasting functional gains for chronic spinal cord injury, a major step forward.

A new deal for the rare isotope Actinium-225 could break a major supply bottleneck, accelerating the development of highly targeted cancer treatments.

With its foundational drug a success, Madrigal bets billions on next-gen siRNA tech, aiming to fuse it with Rezdiffra and dominate MASH treatment.

A national report card gives the U.S. a 'B' on rare disease policy, but stark state-by-state disparities leave millions vulnerable to financial ruin.

A new strategic alliance aims to bring complex peptide therapies to Europe and India, signaling a shift in global biopharma partnerships and patient access.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

The biotech celebrates its first FDA drug approval, a massive financial boost, and promising new therapies targeting obesity and Alzheimer's disease.